Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases.
Dipak Panigrahy,Allison Gartung,Jun Yang,Haixia Yang,Molly M Gilligan,Megan L Sulciner,Swati S Bhasin,Diane R Bielenberg,Jaimie Chang,Birgitta A Schmidt,Julia Piwowarski,Anna Fishbein,Dulce Soler-Ferran,Matthew A Sparks,Steven J Staffa,Vidula Sukhatme,Bruce D Hammock,Mark W Kieran,Sui Huang,Manoj Bhasin,Charles N Serhan,Vikas P Sukhatme
DOI: https://doi.org/10.1172/JCI127282
IF: 19.456
2019-01-01
Journal of Clinical Investigation
Abstract:Cancer therapy is a double-edged sword, as surgery and chemotherapy can induce an inflammatory/immunosuppressive injury response that promotes dormancy escape and tumor recurrence. We hypothesized that these events could be altered by early blockade of the inflammatory cascade and/or by accelerating the resolution of inflammation. Preoperative, but not postoperative, administration of the nonsteroidal antiinflammatory drug ketorolac and/or resolvins, a family of specialized proresolving autacoid mediators, eliminated micrometastases in multiple tumor-resection models, resulting in long-term survival. Ketorolac unleashed anticancer T cell immunity that was augmented by immune checkpoint blockade, negated by adjuvant chemotherapy, and dependent on inhibition of the COX-1/thromboxane A(2) (TXA(2)) pathway. Preoperative stimulation of inflammation resolution via resolvins (RvD2, RvD3, and RvD4) inhibited metastases and induced T cell responses. Ketorolac and resolvins exhibited synergistic antitumor activity and prevented surgery-or chemotherapy-induced dormancy escape. Thus, simultaneously blocking the ensuing proinflammatory response and activating endogenous resolution programs before surgery may eliminate micrometastases and reduce tumor recurrence.